Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

Sequestration Pattern in ITP Liver/Spleen Scan Correlates with the Presence of Anti-Glycoprotein V Antibodies in ITP Patients

Sufia N. Amini, MD, Annemieke Sobels, MSc, Christianne Duchateau, MD, Masja De Haas, MD PhD, Leendert Porcelijn, MD, Roger Schutgens, MD PhD, Jaap Jan Zwaginga, MD PhD, Martin R. Schipperus, MD PhD

Blood (2017) 130 (Supplement 1): 1046.

https://doi.org/10.1182/blood.V130.Suppl_1.1046.1046

Published: 2017

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

Journal Articles

Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

Blood (2016) 128 (22): 2555.

https://doi.org/10.1182/blood.V128.22.2555.2555

Published: 2016

Journal Articles

Cathepsin B Mediated Lysosomal Degradation in Macrophages Controls the Pharmacokinetics of the Therapeutic Protein Asparaginase

Laurens T Van Der Meer, PhD, Samantha YA Terry, PhD, Dorette van Ingen Schenau, MSc, Kiki Andree, MSc, Gerben M Franssen, BSc, Debbie Roeleveld, MSc, Bart Metselaar, PhD, Thomas Reinheckel, PhD, Peter M Hoogerbrugge, MD PhD, Otto C Boerman, PhD, Frank N van Leeuwen, PhD

Blood (2015) 126 (23): 3768.

https://doi.org/10.1182/blood.V126.23.3768.3768

Published: 2015

Journal Articles

Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data

Silvia Cantoni, MD, Monica Carpenedo, MD, Domenico Sica Lanfranco, MD, Michele Nichelatti, Massimo Milella, MD, Angela Centroni, MD, Roberto Cairoli, MD

Blood (2015) 126 (23): 2248.

https://doi.org/10.1182/blood.V126.23.2248.2248

Published: 2015

Journal Articles

Activating KIR: iN Kase of KIR-ligand mismatch

Nina Shah

Blood (2015) 125 (20): 3045–3046.

https://doi.org/10.1182/blood-2015-03-634733

Published: 2015

Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2014) 124 (21): 3708.

https://doi.org/10.1182/blood.V124.21.3708.3708

Published: 2014

Journal Articles

A Phase 2 Open-Label Safety and Tolerability Study of Single Intravenous (IV) Escalating Doses of 90 Yttrium-Labeled Antiferritin Antibodies ( 90 Y-Antiferritin) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Didier Decaudin, MD, Alain Pecking, MD, François Lokiec, PhD, Jean Kadouche, PhD, Stephane E. Allard, MD

Blood (2014) 124 (21): 5468.

https://doi.org/10.1182/blood.V124.21.5468.5468

Published: 2014

Journal Articles

The Therapeutic Protein Asparaginase Is Efficiently Cleared By Bone Barrow and Spleen Resident Macrophages

Laurens T van der Meer, PhD, Samantha YA Terry, PhD, Dorette S van IngenSchenau, MSc, Kiki C Andree, MSc, Peter M Hoogerbrugge, MD PhD, Otto C Boerman, PhD, Frank N van Leeuwen, PhD

Blood (2014) 124 (21): 3630.

https://doi.org/10.1182/blood.V124.21.3630.3630

Published: 2014

Journal Articles

18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis

Annalisa Andreoli, MD, Laetitia Vercellino, Mathieu-John Ouvrier, Emmanuelle Barré, Bruno Cassinat, PharmD, PhD, Virginie de Beco, Jean-Marc Zini, MD, PhD, Pascal Merlet, MD, Christine Dosquet, MD, Christine Chomienne, MD, PhD, Marie-Elisabeth Toubert, Jean-Jacques Kiladjian, MD, PhD

Blood (2012) 120 (21): 1741.

https://doi.org/10.1182/blood.V120.21.1741.1741

Published: 2012

Journal Articles

Use of 111-Indium–labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects

Neda Farahi, Nanak R. Singh, Sarah Heard, Chrystalla Loutsios, Charlotte Summers, Chandra K. Solanki, Kishor Solanki, Kottekkattu K. Balan, Prina Ruparelia, A. Michael Peters, Alison M. Condliffe, Edwin R. Chilvers

Blood (2012) 120 (19): 4068–4071.

https://doi.org/10.1182/blood-2012-07-443424

Published: 2012

Includes: Supplemental data

Journal Articles

PGE 2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells

Ravikumar Muthuswamy, Jan Mueller-Berghaus, Uwe Haberkorn, Todd A. Reinhart, Dirk Schadendorf, Pawel Kalinski

Blood (2010) 116 (9): 1454–1459.

https://doi.org/10.1182/blood-2009-12-258038

Published: 2010

Includes: Supplemental data

Journal Articles

Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).

Amrita Krishnan, MD, FACP, Andrew Raubitschek, MD, Auayporn P. Nademanee, MD, N. Kogut, MD, Leslie Popplewell, MD, Ni-Chun Tsai, Joycelynne Palmer, PhD, Jennifer Simpson, Laura Federico, Dave Yamauchi, MD, Stephen J. Forman, MD

Blood (2009) 114 (22): 2323.

https://doi.org/10.1182/blood.V114.22.2323.2323

Published: 2009

Journal Articles

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.

Amrita Krishnan, MD, FACP, Andrew Raubitschek, MD, Joycelynne Palmer, PHD, Auayporn P. Nademanee, MD, N. Kogut, MD, Dave Yamauchi, MD, Leslie Popplewell, MD, Laura Federico, Jennifer Simpson, Ni-Chun Tsai, Stephen J Forman, MD

Blood (2009) 114 (22): 3423.

https://doi.org/10.1182/blood.V114.22.3423.3423

Published: 2009

Journal Articles

Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)–infected nonhuman primates

Michele Di Mascio, Chang H. Paik, Jorge A. Carrasquillo, Jin-Soo Maeng, Beom-Su Jang, In Soo Shin, Sharat Srinivasula, Russ Byrum, Achilles Neria, William Kopp, Marta Catalfamo, Yoshiaki Nishimura, Keith Reimann, Malcolm Martin, H. Clifford Lane

Blood (2009) 114 (2): 328–337.

https://doi.org/10.1182/blood-2008-12-192203

Published: 2009

Includes: Supplemental data

Journal Articles

A Phase I Study of Bortezomib (Velcade ® ) Plus 90 yttrium Labeled Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Anne Beaven, MD, Thomas C. Shea, MD, Dominic T Moore, PhD, Tatyana Feldman, MD, Anastasia Ivanova, PhD, Madlyn Ferraro, RN, OCN, CCRC, Peggy Ford, RN, Judy Smith, RN, Andre Goy, MD

Blood (2008) 112 (11): 4944.

https://doi.org/10.1182/blood.V112.11.4944.4944

Published: 2008

Journal Articles

Moderate Pharmacological Platelet Count Reduction Limits Thrombus Formation without Hemostatic Impairment in Primates

Erik I Tucker, Ulla M Marzec, Sawan Hurst, András Gruber, MD, Stephen R Hanson, PhD

Blood (2008) 112 (11): 1033.

https://doi.org/10.1182/blood.V112.11.1033.1033

Published: 2008

Journal Articles

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Marta Cremonesi, MPh, Margherita Clerici, RN, Davide Radice, ST, Stefano Papi, PhD, Liliana Calabrese, DM, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 1890.

https://doi.org/10.1182/blood.V110.11.1890.1890

Published: 2007

Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 2558.

https://doi.org/10.1182/blood.V110.11.2558.2558

Published: 2007

NARROW

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Sequestration Pattern in ITP Liver/Spleen Scan Correlates with the Presence of Anti-Glycoprotein V Antibodies in ITP Patients

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

Cathepsin B Mediated Lysosomal Degradation in Macrophages Controls the Pharmacokinetics of the Therapeutic Protein Asparaginase

Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data

Activating KIR: iN Kase of KIR-ligand mismatch

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

A Phase 2 Open-Label Safety and Tolerability Study of Single Intravenous (IV) Escalating Doses of 90 Yttrium-Labeled Antiferritin Antibodies ( 90 Y-Antiferritin) in Patients with Relapsed or Refractory Hodgkin Lymphoma

The Therapeutic Protein Asparaginase Is Efficiently Cleared By Bone Barrow and Spleen Resident Macrophages

18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis

Use of 111-Indium–labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects

PGE 2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells

Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.

Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)–infected nonhuman primates

A Phase I Study of Bortezomib (Velcade ® ) Plus 90 yttrium Labeled Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Moderate Pharmacological Platelet Count Reduction Limits Thrombus Formation without Hemostatic Impairment in Primates

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only